Latest Administration News

Firebrick Pharma has commenced commercial manufacturing and export of its new Nasodine Throat Spray, marking a significant step in its international expansion. The company also reported a 15% increase in cash sales and reduced operating costs, signalling improving financial health.

Grand Gulf Energy has progressed its Petroleum Exploration Licence application offshore Namibia and continued development discussions for its Red Helium Project, maintaining a disciplined capital approach during the December 2025 quarter.

Harris Technology Group Limited reported a 16% increase in Q2 FY26 sales, driven by strong demand for refurbished technology products, alongside positive operating cash flow and improved gross margins.

Key Petroleum Limited progresses its Potential Commercial Area applications in Queensland’s Cooper-Eromanga Basin, anticipating government approval by year-end, while planning a capital raise to bolster its limited cash reserves.

CAQ Holdings reported an 8% drop in leasing revenue for the December 2025 quarter amid persistently high vacancy rates, yet anticipates improved rental income following new tenancy negotiations on Hainan Island.

Metal Bank Limited ended December 2025 with nearly $2 million in cash and has since bolstered its liquidity through a significant asset sale and share placement. These moves position the company for sustained exploration activity amid cautious operating cash flows.

Australia United Mining reported a productive quarter at its Forsayth project with gold-silver output, but heavy rains forced a halt to mining activities. The company faces a tight cash position, relying on related party loans and potential asset sales to sustain operations.

Highfield Resources has secured a A$10 million investment from existing strategic shareholders, extending its financial runway through early 2027 while awaiting a critical Spanish Supreme Court ruling on its Goyo mining permit appeal.

TMK Energy Limited has delivered a record-breaking quarter of gas production alongside significant cost reductions, setting the stage for a pivotal year focused on commercialising its vast resource base through new partnerships.

Nexsen Limited has won a $500,000 non-dilutive grant to extend its rapid Group B Streptococcus diagnostic technology into neonatal care, opening a significant new market opportunity.

Island Pharmaceuticals has secured key regulatory milestones for its antiviral Galidesivir, including FDA confirmation of the Animal Rule pathway and Priority Review Voucher eligibility, while strengthening US biodefense ties and expanding patent protection.

Canadian Phosphate Limited reported a solid cash position of AUD 2.44 million at the end of December 2025, supported by financing activities and ongoing preparations for bulk sample mining in Canada.